Generic drug of Xatral LP
Therapeutic class: Urology nephrology
active ingredients: Alfuzosin
laboratory: Teva Sante
Sustained release tablet
Box of 30
Treatment of moderate to severe functional symptoms of benign prostatic hypertrophy (BPH).
Dosage ALFUZOSINE LP TEVA 10 mg prolonged release tablet Box of 30
The prolonged release tablet should be swallowed whole with a glass of water, without being crushed, chewed or divided (see Warnings and Precautions ).
The first dose should be taken at bedtime. Alfuzosin 10 mg prolonged-release tablets should be taken daily, immediately after the same meal.
The recommended dose is one 10 mg tablet daily.
Elderly (over 65 years old)
See "Adults". Data on pharmacokinetics and safety of use show that generally, there is no need to reduce the dose in the elderly.
Mild to moderate renal impairment (creatinine clearance> 30 ml / min)
Dosage adjustment is not usually necessary (see section 5.2 ).
Severe renal insufficiency (creatinine clearance <30 ml / min)
Due to the lack of safety data, alfuzosin 10 mg prolonged-release tablets should not be prescribed in patients with severe renal impairment (see Warnings and Precautions section). employment ).
Alfuzosin 10 mg prolonged release tablets are contraindicated in patients with hepatic impairment. In the opinion of the physician, a preparation containing a lower dose of alfuzosin hydrochloride may be considered appropriate. For dosing recommendations the SPC of the corresponding specialty should be consulted.
ALFUZOSINE TEVA LP 10 mg is not indicated in children.
· Persistence with alfuzosin, other quinazolines (eg terazosin, doxazosin) or with any of the excipients.
· Orthostatic hypotension.
· Severe hepatic insufficiency.
· A combination with other alpha-1 blockers.
Adverse effects Alfuzosine LP Teva
The undesirable effects considered to be possibly related to the treatment are listed below by organ system classes and by absolute frequency. The defined frequencies are: very frequent (≥1 / 10); frequent (≥ 1/100 to <1/10); uncommon (≥ 1/1000 to <1/100); rare (≥ 1/10 000 to <1/1000); very rare (<1 / 10, 000); indeterminate frequency (can not be estimated based on available data).
Blood and lymphatic system disorders
Nervous system disorders
Dizziness / tiredness, vertigo, headache
Intraoperative flaccid iris syndrome
Aggravation or recurrence of angina in patients with pre-existing coronary artery disease (see Warnings and Precautions section )
Orthostatic hypotension (at the beginning of treatment, mainly because of a dose that is too high, or if treatment is resumed after a short interruption)
Respiratory, thoracic and mediastinal disorders
Nausea, abdominal pain, diarrhea, dry mouth
Hepatocellular lesion, cholestatic liver disease
Skin and subcutaneous tissue disorders
Urinary angioneurotic edema
Disorders of reproductive organs and breast
General disorders and administration site conditions
Edema, chest pain (see section Warnings and precautions for use )